Dogwood Therapeutics announces press release availability
DWTX•Halneuron Phase 2b trial enrollment update
Dogwood Therapeutics enrolled the first 200 patients in its Halneuron Phase 2b HAL-CINP trial for chemotherapy-induced neuropathic pain.
Top-line results from the four-week study remain targeted for fall 2026.
An independent unblinded statistical review in December flagged separation from placebo on pain improvement; dropout rate reported at 4.5%.
